Log InSign Up
MissionModelBlogPricingVitaeLeaderboardLibrary

BCTX

StatementStatement RatioRatio
NewsNews
Yahoo Finance Google Finance Market Beat Bar Chart

BriaCell Therapeutics Corp. Common Shares (NASDAQ:BCTX)

Real-time price： | Most recent change：0.00%

BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada....

+See More


Here we provide our AYA proprietary alpha stock signals for all premium members on our AYA fintech network platform. Specifically, a high Fama-French multi-factor dynamic conditional alpha suggests that the stock is likely to consistently outperform the broader stock market benchmarks such as S&P 500, Dow Jones, Nasdaq, Russell 3000, MSCI USA, and MSCI World etc. Since March 2023, our proprietary alpha stock signals retain U.S. Patent and Trademark Office (USPTO) fintech patent protection, approval, and accreditation for 20 years. Our homepage and blog articles provide more details on this proprietary alpha stock market investment model with robust long-term historical backtest evidence.

Sharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 4 April 2026

Blog+More

Today, tech titans continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

John Fourier

2026-10-31 12:38:00 Saturday ET

Today, tech titans continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

Today tech titans and billionaires continue to reshape global pharmaceutical investments for both better healthspan and longer lifespan. We discuss, desc

+See More

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and governments.

Jonah Whanau

2019-11-15 13:34:00 Friday ET

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and governments.

The Economist offers a special report that the new normal state of economic affairs shines fresh light on the division of labor between central banks and go

+See More

Many young and mid-career Americans fall into the financial distress trap in rural communities.

John Fourier

2019-08-01 11:33:00 Thursday ET

Many young and mid-career Americans fall into the financial distress trap in rural communities.

Many young and mid-career Americans fall into the financial distress trap in rural communities. A recent analysis of 25,800 zip codes for 99% of the U.S. po

+See More

President Trump threatens to shut down the government if Democrats refuse to help approve $5 billion border wall finance.

Joseph Corr

2018-12-18 10:38:00 Tuesday ET

President Trump threatens to shut down the government if Democrats refuse to help approve $5 billion border wall finance.

President Trump threatens to shut down the U.S. government in 2019 if Democrats refuse to help approve $5 billion public finance for the southern border wal

+See More

Neoliberal public choice continues to spin national taxation and several other forms of government intervention.

Peter Prince

2019-01-07 18:42:00 Monday ET

Neoliberal public choice continues to spin national taxation and several other forms of government intervention.

Neoliberal public choice continues to spin national taxation and several other forms of government intervention. The key post-crisis consensus focuses on go

+See More

New York Fed CEO John Williams listens to sharp share price declines as part of the data-dependent interest rate policy.

Dan Rochefort

2019-01-02 06:28:00 Wednesday ET

New York Fed CEO John Williams listens to sharp share price declines as part of the data-dependent interest rate policy.

New York Fed CEO John Williams listens to sharp share price declines as part of the data-dependent interest rate policy. The Federal Reserve can respond to

+See More